Quarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar	2011	5983	98.9%	93.0%	97.7%	93.5%	95.9%	~
Apr-June	2011	6145	98.4%	92.7%	96.9%	93.1%	95.3%	~
July-Sept	2011	6403	98.5%	92.8%	96.8%	93.5%	95.4%	~
Oct-Dec	2011	6240	98.3%	93.3%	96.9%	94.2%	95.7%	~
Jan-Mar	2012	6182	98.5%	93.7%	97.1%	94.8%	95.9%	~
Apr-June	2012	6148	98.6%	95.3%	97.1%	95.8%	95.7%	~
July-Sept	2012	6505	98.6%	95.4%	97.2%	95.5%	95.7%	~
Oct-Dec	2012	6562	98.7%	95.9%	97.2%	96.4%	96.5%	~
Jan-Mar	2013	6159	98.4%	95.3%	97.1%	95.8%	95.9%	~
Apr-June	2013	6027	98.7%	96.1%	~	96.2%	96.4%	~
July-Sept	2013	6576	98.8%	96.0%	~	95.9%	96.0%	~
Oct-Dec	2013	6260	98.6%	96.3%	~	96.3%	96.5%	~
Jan-Mar	2014	6229	98.5%	96.1%	~	96.1%	96.3%	~
Apr-June	2014	6185	98.9%	96.4%	~	96.2%	96.3%	~
July-Sept	2014	6443	98.7%	96.4%	~	96.8%	96.5%	~
Oct-Dec	2014	6421	98.4%	95.5%	~	95.9%	95.9%	~
Jan-Mar	2015	5816	97.9%	94.5%	~	95.0%	94.7%	~
Apr-June	2015	5914	98.2%	96.1%	~	95.9%	95.8%	~
July-Sept	2015	6466	98.3%	95.8%	~	95.8%	95.8%	~
Oct-Dec	2015	5959	98.3%	95.5%	~	96.0%	95.9%	~
Jan-Mar	2016	5923	98.3%	95.9%	~	96.3%	95.9%	~
Apr-June	2016	5978	98.3% 97.9%	95.9%	~	95.5%	95.3%	~
•		6521						~
July-Sept	2016		97.9%	94.5%	~	94.9%	95.0%	~
Oct-Dec	2016	6162	97.9%	94.8%	~	95.2%	94.9%	~
Jan-Mar	2017	5765	98.0%	94.7%	~	95.0%	94.8%	~
Apr-June	2017	5937	97.9%	94.8%	~	95.1%	95.0%	~
July-Sept	2017	6524	97.9%	94.6%	~	94.9%	94.8%	94.1%
Oct-Dec	2017	6238	97.7%	93.8%	~	94.6%	94.4%	94.1%
Jan-Mar	2018	5781	98.0%	94.6%	~	95.7%	95.0%	94.6%
Apr-June	2018	5995	97.5%	93.4%	~	93.8%	93.7%	93.4%
July-Sept	2018	6363	97.4%	93.6%	~	94.1%	93.9%	93.7%
Oct-Dec	2018	6133	96.9%	92.3%	~	92.5%	92.5%	92.2%
Jan-Mar	2019	5709	96.5%	91.2%	~	92.5%	91.7%	91.4%
Apr-June	2019	5656	95.8%	91.4%	~	91.8%	91.6%	91.6%
July-Sept	2019	6140	96.0%	92.1%	~	92.5%	92.2%	92.2%
Oct-Dec	2019	5883	96.0%	92.7%	~	93.5%	92.8%	92.6%
Jan-Mar	2020	5431	95.6%	92.2%	~	92.6%	92.3%	92.1%
Apr-June	2020	5806	95.5%	92.2%	~	92.6%	92.2%	92.3%
July-Sept	2020	6080	95.8%	91.9%	~	92.3%	92.1%	91.8%
Oct-Dec	2020	5743	96.0%	92.3%	~	92.7%	92.5%	92.2%
Jan-Mar	2021	5451	96.2%	91.5%	~	92.0%	91.7%	91.2%
Apr-June	2021	5549	95.9%	92.4%	~	92.9%	92.6%	91.9%
July-Sept	2021	5993	95.4%	91.1%	~	91.5%	91.5%	90.5%
Oct-Dec	2021	5651	94.7%	91.3%	~	91.5%	91.3%	90.4%
Jan-Mar	2022	5315	95.2%	91.9%	~	92.0%	92.0%	91.3%
Apr-June	2022	5272	94.4%	90.5%	~	90.6%	90.6%	89.5%
July-Sept	2022	5731	94.0%	89.4%	~	89.6%	89.5%	88.9%
Oct-Dec	2022	5434	94.4%	89.5%	~	90.2%	89.8%	89.0%
Jan-Mar	2023	5384	94.0%	89.4%	~	91.8%	89.8%	89.2%
Apr-June	2023	5342	93.8%	89.3%	~	89.8%	89.8%	88.6%
Jul-Sept	2023	6007	93.1%	88.8%	~	89.1%	89.0%	88.1%
Oct-Dec	2023	5646	93.7%	89.5%	~	89.7%	89.7%	88.7%
Jan-Mar	2023	5159	93.6%	89.3%	~	89.4%	89.4%	88.3%
					~			
Apr-June Jul-Sept	2024 2024	5117	93.6%	89.9%	~	90.0%	90.1%	89.0% 89.2%
	2024	5478	93.6%	90.3%	~	90.8%	90.2%	89.2%

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 =
Tet3 =
Pert3 =
Pol (IPV)3 =
Hib3 =
HepB3 =

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2 Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar 2020

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013

PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)

MMR1 = Measles, mumps, and rubella vaccine (1 dose)

Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006)

MenB3 = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in BHSCT: Completed Primary Immunisations by 24 months

Quarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar	2011	1086	98.2%	88.8%	96.1%	88.6%	92.6%	~
Apr-June	2011	1141	97.1%	88.9%	94.7%	89.8%	92.4%	~
July-Sept	2011	1185	96.6%	88.5%	94.3%	89.5%	91.9%	~
Oct-Dec	2011	1153	96.4%	89.4%	95.1%	89.9%	92.5%	~
Jan-Mar	2012	1066	97.4%	89.7%	94.6%	90.4%	92.5%	~
Apr-June	2012	1141	98.1%	92.8%	95.7%	92.7%	93.1%	~
July-Sept	2012	1218	96.9%	92.5%	94.6%	92.2%	92.5%	~
Oct-Dec	2012	1313	97.3%	93.6%	94.5%	94.0%	94.1%	~
Jan-Mar	2013	1158	97.4%	93.1%	94.8%	93.3%	93.8%	~
Apr-June	2013	1092	97.8%	93.7%	~	93.5%	93.4%	~
July-Sept	2013	1264	97.9%	94.9%	~	94.2%	94.0%	~
Oct-Dec	2013	1214	97.2%	93.7%	~	92.6%	93.3%	~
Jan-Mar	2014	1228	97.0%	93.7%	~	93.2%	93.5%	~
Apr-June	2014	1163	98.1%	94.5%	~	93.4%	94.0%	~
July-Sept	2014	1211	97.2%	94.0%	~	95.2%	93.9%	~
Oct-Dec	2014	1218	97.0%	93.5%	~	93.4%	93.1%	~
Jan-Mar	2015	1111	96.0%	90.9%	~	91.9%	91.0%	~
Apr-June	2015	1115	96.3%	93.1%	~	92.6%	92.3%	~
July-Sept	2015	1258	97.0%	93.7%	~	93.2%	93.3%	~
Oct-Dec	2015	1256	96.1%	93.7%	~	93.2%	93.3%	~
Jan-Mar	2015	1097	97.1%	93.6%	~	91.6%	93.5%	~
	2016			93.6%	~			
Apr-June		1155	96.6%			91.8%	91.6%	~
July-Sept	2016	1190	96.5%	90.0%	~	90.4%	90.0%	~
Oct-Dec	2016	1145	95.3%	89.8%	~	90.1%	89.8%	~
Jan-Mar	2017	1105	96.5%	90.6%	~	90.5%	90.0%	~
Apr-June	2017	1121	95.9%	92.3%	~	92.1%	91.9%	~
July-Sept	2017	1151	96.4%	91.3%	~	91.1%	90.4%	90.0%
Oct-Dec	2017	1127	95.0%	88.7%	~	89.1%	89.0%	88.3%
Jan-Mar	2018	1058	95.8%	91.4%	~	91.6%	91.2%	91.1%
Apr-June	2018	1091	95.1%	89.2%	~	89.5%	88.9%	88.9%
July-Sept	2018	1161	95.1%	89.0%	~	88.8%	88.5%	88.2%
Oct-Dec	2018	1194	94.9%	86.8%	~	86.9%	86.9%	86.3%
Jan-Mar	2019	1046	93.9%	85.3%	~	86.3%	85.5%	85.4%
Apr-June	2019	995	90.3%	82.8%	~	83.7%	83.0%	83.0%
July-Sept	2019	1086	92.1%	84.9%	~	85.5%	85.0%	85.1%
Oct-Dec	2019	1080	91.7%	87.2%	~	87.4%	86.8%	86.6%
Jan-Mar	2020	1014	91.9%	86.0%	~	87.0%	85.7%	86.0%
Apr-June	2020	1057	92.2%	86.7%	~	87.1%	86.1%	86.0%
July-Sept	2020	1161	92.5%	85.5%	~	85.6%	85.1%	85.3%
Oct-Dec	2020	1067	93.1%	87.9%	~	88.3%	88.1%	87.6%
Jan-Mar	2021	986	93.4%	85.2%	~	85.3%	84.6%	83.3%
Apr-June	2021	1053	93.2%	86.1%	~	87.0%	86.2%	84.8%
July-Sept	2021	1127	92.4%	83.4%	~	83.8%	83.8%	82.2%
Oct-Dec	2021	1055	90.0%	84.1%	~	83.8%	84.0%	82.4%
Jan-Mar	2022	983	90.8%	85.0%	~	84.2%	84.8%	83.2%
Apr-June	2022	1005	89.1%	81.1%	~	81.1%	80.7%	78.7%
July-Sept	2022	1083	88.6%	81.1%	~	80.6%	80.7%	79.1%
Oct-Dec	2022	1015	88.5%	80.0%	~	79.6%	80.1%	77.6%
Jan-Mar	2023	1015	87.8%	79.8%	~	90.4%	80.2%	78.3%
Apr-June	2023	960	86.1%	79.0%	~	78.9%	79.0%	75.6%
Jul-Sept	2023	1113	88.8%	82.8%	~	82.4%	82.3%	80.0%
Oct-Dec	2023	1056	88.3%	82.5%	~	82.2%	82.7%	80.2%
Jan-Mar	2023	891	89.0%	84.6%	~	83.8%	84.0%	81.0%
Apr-June	2024	924	89.9%	84.8%	~	85.0%	85.0%	82.3%
Jul-Sept	2024	1023	89.1%	83.6%	~	83.1%	83.0%	81.3%
Jui-Sept	2024	1023	09.1%	03.0%	~	03.1%	03.0%	01.3%

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 = Tet3 = Pert3 = Pol (IPV)3 = HepB3 =

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar

Infant MenC = PCV Booster = MMR1 = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013

Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006) Measles, mumps, and rubella vaccine (1 dose) Hib/MenC booster vaccine (1 dose) (introduced September 2006)

Hib/MenC = MenB3 = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in SEHSCT: Completed Primary Immunisations by 24 months

Quarter		No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar		1066	98.4%	91.3%	97.3%	92.4%	94.7%	~
Apr-June	e 2011	1157	98.1%	91.4%	96.9%	91.8%	94.4%	~
July-Sep	t 2011	1226	98.5%	92.4%	97.0%	93.6%	95.6%	~
Oct-Dec	2011	1132	97.7%	92.8%	96.5%	94.2%	95.1%	~
Jan-Mar	2012	1096	98.6%	93.8%	97.7%	94.3%	95.3%	~
Apr-June	2012	1113	98.4%	95.0%	97.2%	95.6%	95.5%	~
July-Sep		1190	98.7%	95.1%	97.6%	95.5%	95.9%	~
Oct-Dec		1183	98.7%	95.9%	97.6%	96.3%	96.1%	~
Jan-Mar		1077	98.1%	95.7%	97.0%	96.4%	96.4%	~
Apr-June		1120	99.0%	96.3%	~	96.3%	96.9%	~
July-Sep		1231	98.4%	95.7%	~	95.9%	96.3%	~
Oct-Dec		1147	98.8%	96.7%	~	97.6%	97.7%	~
Jan-Mar		1154			~			~
			99.0%	97.2%		97.9%	98.2%	
Apr-June		1106	99.2%	96.0%	~	96.1%	96.1%	~
July-Sep		1110	98.6%	96.2%	~	96.3%	96.4%	~
Oct-Dec		1158	99.2%	96.7%	~	97.8%	97.2%	~
Jan-Mar		1082	97.0%	94.5%	~	94.8%	94.7%	~
Apr-June		1092	98.5%	96.6%	~	96.4%	96.2%	~
July-Sep	t 2015	1157	98.9%	96.1%	~	95.9%	95.9%	~
Oct-Dec	2015	1028	98.2%	95.6%	~	96.3%	96.1%	~
Jan-Mar	2016	1082	98.4%	95.6%	~	95.7%	95.6%	~
Apr-June	2016	1070	97.9%	95.5%	~	96.3%	96.3%	~
July-Sep		1201	97.9%	94.6%	~	95.3%	95.6%	~
Oct-Dec		1085	98.0%	95.4%	~	96.2%	96.2%	~
Jan-Mar		1028	98.0%	94.9%	~	94.7%	94.4%	~
Apr-June		1078	97.2%	94.0%	~	95.1%	94.2%	_
July-Sep		1217	97.9%	95.5%	~	95.9%	95.4%	95.5%
Oct-Dec		1115	98.4%	95.2%	~	96.1%	95.6%	95.5%
Jan-Mar		1049	98.3%	95.2%	~	95.3%	95.0%	94.9%
Apr-June		1097	97.4%	92.9%	~	93.5%	93.7%	93.6%
July-Sep		1166	97.7%	93.7%	~	94.1%	93.7%	93.8%
Oct-Dec		1063	97.1%	93.7%	~	93.9%	93.7%	93.5%
Jan-Mar		1056	96.7%	92.2%	~	92.9%	92.9%	92.8%
Apr-June		976	96.2%	93.9%	~	93.5%	93.3%	93.8%
July-Sep	t 2019	1027	96.4%	93.7%	~	94.0%	94.2%	94.0%
Oct-Dec		1053	96.6%	93.8%	~	93.8%	93.5%	93.7%
Jan-Mar	2020	975	95.9%	93.3%	~	93.9%	93.6%	93.6%
Apr-June	2020	1041	95.8%	92.3%	~	93.1%	92.4%	92.6%
July-Sep	t 2020	1101	95.6%	92.3%	~	92.9%	92.6%	92.3%
Oct-Dec		1036	97.4%	93.0%	~	93.1%	93.0%	92.9%
Jan-Mar		961	95.5%	91.1%	~	91.6%	91.1%	90.5%
Apr-June		1007	95.5%	91.6%	~	92.4%	92.0%	91.5%
July-Sep		1061	95.3%	89.8%	~	90.4%	90.0%	89.1%
Oct-Dec		967	94.3%	90.3%	~	90.3%	90.1%	88.3%
Jan-Mar		960	95.5%	90.7%	~	91.3%	91.1%	90.3%
Apr-June		907	93.6%	91.4%	~	91.5%	91.8%	90.0%
July-Sep		1024	92.5%	88.2%	~	88.3%	88.3%	87.4%
Oct-Dec		931	93.3%	88.1%	~	88.3%	88.3%	87.3%
Jan-Mar		920	93.0%	89.6%	~	89.9%	90.0%	89.7%
Apr-June		963	92.2%	88.0%	~	88.7%	88.6%	87.4%
		1042	91.1%	87.6%	~	87.7%	87.5%	86.7%
Jul-Sept		4040	93.5%	89.8%	~	89.7%	89.9%	88.9%
Jul-Sept Oct-Dec		1013	93.5%				00.070	
•		948	90.7%	87.2%	~	87.7%	87.3%	86.2%
Oct-Dec	2024							

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 = Tet3 = Pert3 = Pol (IPV)3 = Hib3 = HepB3 =

Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar 2020

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013

PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006) MMR1 =

Measles, mumps, and rubella vaccine (1 dose)

Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006) MenB3 = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in NHSCT: Completed Primary Immunisations by 24 months

Quarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar	2011	1377	99.5%	94.9%	98.3%	95.4%	97.4%	~
Apr-June	2011	1438	98.4%	93.7%	97.0%	94.1%	96.6%	~
July-Sept	2011	1498	99.2%	93.7%	98.0%	94.6%	96.1%	~
Oct-Dec	2011	1487	98.9%	93.4%	97.6%	94.8%	96.4%	~
Jan-Mar	2012	1550	98.5%	94.5%	97.1%	95.9%	96.8%	~
Apr-June	2012	1510	99.1%	96.3%	97.5%	97.0%	96.9%	~
July-Sept	2012	1544	98.8%	95.1%	97.6%	95.3%	95.5%	~
Oct-Dec	2012	1565	99.2%	96.6%	98.0%	97.1%	97.1%	~
Jan-Mar	2013	1490	98.8%	95.1%	97.7%	95.8%	96.2%	~
Apr-June	2013	1477	98.8%	96.4%	~	96.6%	96.5%	~
July-Sept	2013	1550	99.0%	96.2%	~	96.1%	96.3%	~
Oct-Dec	2013	1455	99.0%	97.0%	~	97.3%	97.5%	~
Jan-Mar	2014	1466	98.6%	95.6%	~	96.2%	96.3%	~
Apr-June	2014	1456	98.6%	95.5%	~	96.1%	95.9%	~
July-Sept	2014	1553	99.0%	97.1%	~	97.4%	97.1%	~
Oct-Dec	2014	1536	98.6%	95.0%	~	96.2%	96.4%	~
Jan-Mar	2015	1408	99.1%	93.6%	~	94.9%	94.7%	~
Apr-June	2015	1442	98.2%	96.0%	~	96.0%	96.1%	~
July-Sept	2015	1558	98.3%	96.7%	~	96.5%	96.7%	~
Oct-Dec	2015	1448	98.8%	96.7%	~	97.3%	97.2%	~
	2015	1429					96.7%	
Jan-Mar			98.5%	96.4%	~	97.5%		~
Apr-June	2016	1393	98.3%	96.6%	~	96.8%	96.7%	~
July-Sept	2016	1571	98.2%	95.4%	~	96.1%	96.2%	~
Oct-Dec	2016	1515	98.7%	95.6%	~	95.9%	95.8%	~
Jan-Mar	2017	1391	98.3%	95.3%	~	95.9%	95.8%	~
Apr-June	2017	1443	99.2%	95.4%	~	96.1%	96.0%	~
July-Sept	2017	1541	98.4%	94.4%	~	94.9%	95.2%	94.2%
Oct-Dec	2017	1490	98.5%	95.2%	~	96.0%	96.0%	95.3%
Jan-Mar	2018	1328	98.9%	95.7%	~	96.8%	96.7%	96.2%
Apr-June	2018	1430	98.0%	94.4%	~	95.4%	95.0%	94.9%
July-Sept	2018	1506	97.9%	95.8%	~	96.5%	96.3%	96.1%
Oct-Dec	2018	1487	97.6%	93.5%	~	93.7%	93.8%	93.5%
Jan-Mar	2019	1371	97.1%	92.6%	~	93.2%	93.1%	93.0%
Apr-June	2019	1343	97.2%	93.0%	~	93.4%	93.4%	93.2%
July-Sept	2019	1505	97.3%	94.1%	~	94.3%	94.4%	94.0%
Oct-Dec	2019	1398	97.4%	95.1%	~	95.6%	95.6%	95.1%
Jan-Mar	2020	1239	96.8%	93.5%	~	93.6%	93.5%	93.3%
Apr-June	2020	1380	96.7%	94.3%	~	95.0%	94.5%	94.6%
July-Sept	2020	1396	96.8%	94.1%	~	94.8%	94.8%	94.5%
Oct-Dec	2020	1355	96.5%	93.7%	~	93.9%	93.8%	93.4%
Jan-Mar	2021	1309	97.3%	93.4%	~	94.1%	94.1%	93.9%
Apr-June	2021	1314	97.6%	95.0%	~	95.7%	95.5%	95.1%
July-Sept	2021	1427	97.1%	93.9%	~	94.3%	94.5%	93.7%
Oct-Dec	2021	1366	96.6%	93.3%	~	93.6%	93.6%	92.5%
Jan-Mar	2022	1229	96.7%	94.1%	~	94.4%	94.5%	93.7%
Apr-June	2022	1302	96.2%	92.7%	~	93.0%	93.1%	92.5%
July-Sept	2022	1392	96.3%	92.2%	~	92.6%	92.5%	92.0%
Oct-Dec	2022	1264	98.1%	93.7%	~	94.1%	93.8%	93.8%
Jan-Mar	2023	1276	95.7%	90.7%	~	91.3%	91.3%	91.1%
Apr-June	2023	1300	96.8%	92.8%	~	93.5%	93.6%	92.7%
Jul-Sept	2023	1387	95.2%	91.3%	~	91.8%	91.9%	91.3%
Oct-Dec	2023	1333	95.1%	90.5%	~	91.1%	91.2%	90.9%
Jan-Mar	2024	1243	96.3%	91.1%	~	91.2%	91.4%	90.9%
Apr-June	2024	1231	95.0%	92.0%	~	92.2%	92.6%	91.3%
Jul-Sept	2024	1337	95.5%	92.5%	~	92.2%	92.4%	91.6%
Jui-Jept	2024	1331	33.376	JZ.J /0	~	JZ.Z/0	JZ.4 /0	31.070

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 = Tet3 = Pert3 = Pol (IPV)3 = Hib3 = HepB3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 20 Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar 2020

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013

PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)

MMR1 = Measles, mumps, and rubella vaccine (1 dose)

Hib/MenC = Hib/MenC booster vaccine (1 dose) (introduced September 2006)

MenB3 = Hib/MenC booster vaccine (1 dose) (introduced September 2006)

Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015)

Vaccination Coverage Statistics for Children in SHSCT: Completed Primary Immunisations by 24 months

Quarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar	2011	1367	99.4%	94.1%	98.7%	94.4%	97.0%	~
Apr-June	2011	1391	99.5%	94.5%	98.0%	94.8%	96.6%	~
July-Sept	2011	1415	98.7%	94.3%	96.9%	94.3%	96.8%	~
Oct-Dec	2011	1417	98.9%	95.1%	97.2%	95.3%	96.6%	~
Jan-Mar	2012	1410	99.1%	94.8%	97.7%	95.7%	96.5%	~
Apr-June	2012	1356	98.8%	96.5%	96.8%	96.8%	96.8%	~
July-Sept	2012	1474	99.1%	97.1%	97.4%	97.0%	97.0%	~
Oct-Dec	2012	1440	99.2%	96.7%	98.1%	96.9%	97.4%	~
Jan-Mar	2013	1369	98.8%	96.2%	97.7%	96.4%	96.1%	~
Apr-June	2013	1291	98.8%	96.6%	~	96.7%	97.1%	~
July-Sept	2013	1447	99.0%	96.2%	~	96.0%	96.3%	~
Oct-Dec	2013	1389	99.1%	96.7%	~	96.5%	96.5%	~
Jan-Mar	2014	1357	99.1%	96.8%	~	96.6%	96.6%	~
Apr-June	2014	1424	98.9%	97.4%	~	97.1%	97.3%	~
July-Sept	2014		99.0%	97.5%		97.1%	97.4%	~
, ,		1542			~			
Oct-Dec	2014	1430	98.6%	95.9%	~	95.5%	95.9%	~
Jan-Mar	2015	1314	98.6%	96.7%	~	96.2%	96.3%	~
Apr-June	2015	1329	98.9%	97.5%	~	96.8%	97.0%	~
July-Sept	2015	1420	98.7%	96.3%	~	96.4%	96.3%	~
Oct-Dec	2015	1377	99.1%	96.4%	~	96.8%	96.7%	~
Jan-Mar	2016	1360	99.0%	97.7%	~	97.0%	97.2%	~
Apr-June	2016	1389	98.1%	95.6%	~	95.7%	96.0%	~
July-Sept	2016	1437	98.2%	95.8%	~	95.2%	95.5%	~
Oct-Dec	2016	1403	98.4%	96.5%	~	95.6%	95.7%	~
Jan-Mar	2017	1319	98.4%	96.7%	~	96.9%	96.8%	~
Apr-June	2017	1322	98.4%	96.3%	~	95.8%	96.1%	~
July-Sept	2017	1501	97.9%	95.1%	~	95.1%	95.4%	94.2%
Oct-Dec	2017	1458	98.1%	94.9%	~	95.3%	95.2%	95.1%
Jan-Mar	2017	1369	98.2%	94.7%	~	94.8%	95.3%	94.5%
Apr-June	2018		98.7%	95.6%	~	94.6%	94.9%	94.1%
•		1381						
July-Sept	2018	1466	97.5%	94.1%	~	94.3%	94.3%	93.9%
Oct-Dec	2018	1398	97.3%	93.9%	~	94.1%	94.3%	93.6%
Jan-Mar	2019	1274	97.2%	92.8%	~	93.2%	93.1%	92.6%
Apr-June	2019	1383	97.2%	94.2%	~	94.2%	94.1%	94.1%
July-Sept	2019	1501	96.8%	93.9%	~	94.0%	93.7%	93.7%
Oct-Dec	2019	1317	97.3%	94.2%	~	94.2%	94.0%	93.8%
Jan-Mar	2020	1263	97.1%	94.2%	~	94.4%	94.6%	93.6%
Apr-June	2020	1353	95.8%	93.1%	~	93.1%	93.3%	93.3%
July-Sept	2020	1435	96.2%	93.2%	~	93.0%	92.7%	92.1%
Oct-Dec	2020	1360	96.5%	93.2%	~	93.2%	93.1%	92.9%
Jan-Mar	2021	1259	96.9%	93.8%	~	94.3%	94.0%	93.6%
Apr-June	2021	1290	95.9%	93.7%	~	93.5%	93.3%	92.6%
July-Sept	2021	1413	96.2%	92.8%	~	92.9%	93.2%	92.2%
Oct-Dec	2021	1344	95.9%	93.1%	~	93.3%	93.2%	92.9%
Jan-Mar	2022	1218	96.6%	93.8%		94.4%	93.8%	93.4%
					~			
Apr-June	2022	1172	95.9%	92.2%	~	92.3%	91.9%	91.5%
July-Sept	2022	1308	96.0%	91.6%	~	91.7%	91.6%	91.2%
Oct-Dec	2022	1251	95.3%	91.4%	~	91.7%	91.8%	91.3%
Jan-Mar	2023	1244	96.9%	93.5%	~	93.7%	93.5%	93.4%
Apr-June	2023	1230	96.4%	93.0%	~	93.0%	92.6%	92.4%
Jul-Sept	2023	1435	94.9%	89.5%	~	90.0%	89.8%	89.5%
Oct-Dec	2023	1319	95.4%	91.7%	~	91.7%	91.7%	90.6%
				04.00/		04.00/	02.00/	91.3%
Jan-Mar	2024	1232	95.3%	91.6%	~	91.8%	92.0%	91.5%
	2024 2024	1232 1227	95.3% 95.0%	91.6% 91.0%	~ ~	91.0%	92.0%	90.9%

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 = Tet3 = Pert3 = Pol (IPV)3 = Hib3 = HepB3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Ma

Infant MenC = PCV Booster = MMR1 = Hib/MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) <u>reporting ceased in April 2013</u> Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006)

Measles, mumps, and rubella vaccine (1 dose)

Hib/MenC booster vaccine (1 dose) (introduced September 2006)

Quarter*	Year	No. in cohort	**DTap/IPV/Hib/HepB	MMR1	MenC	PCV Booster	Hib/MenC	MenB3
Jan-Mar	2011	1087	98.7%	95.3%	97.5%	96.0%	96.9%	~
Apr-June	2011	1018	98.9%	94.4%	97.5%	94.8%	95.8%	~
July-Sept	2011	1079	99.1%	94.9%	97.8%	95.5%	96.5%	~
Oct-Dec	2011	1051	99.1%	95.8%	97.8%	96.6%	97.5%	~
Jan-Mar	2012	1060	99.0%	95.3%	98.2%	97.0%	97.9%	~
Apr-June	2012	1028	98.7%	95.7%	98.1%	96.0%	95.7%	~
July-Sept	2012	1079	99.4%	97.1%	99.0%	97.5%	97.6%	~
Oct-Dec	2012	1061	99.1%	96.8%	97.9%	98.0%	97.9%	~
Jan-Mar	2013	1065	99.0%	96.6%	98.1%	97.0%	97.0%	~
Apr-June	2013	1047	98.9%	97.2%	~	97.8%	97.9%	~
July-Sept	2013	1084	99.4%	97.4%	~	97.3%	97.0%	~
Oct-Dec	2013	1055	98.8%	97.3%	~	97.4%	97.6%	~
Jan-Mar	2014	1024	98.8%	97.3%	~	97.0%	96.9%	~
Apr-June	2014	1036	99.8%	98.8%	~	98.6%	98.6%	~
July-Sept	2014	1027	99.6%	97.0%	~	97.5%	97.3%	~
Oct-Dec		1079						
	2014		98.5%	96.7%	~	96.8%	97.1%	~
Jan-Mar	2015	901	98.6%	97.1%	~	97.3%	97.1%	~
Apr-June	2015	936	98.8%	97.2%	~	97.6%	97.4%	~
July-Sept	2015	1073	99.1%	96.2%	~	96.8%	96.8%	~
Oct-Dec	2015	988	99.1%	96.8%	~	97.5%	97.4%	~
Jan-Mar	2016	955	98.3%	95.8%	~	98.1%	96.5%	~
Apr-June	2016	971	98.2%	95.6%	~	97.0%	95.9%	~
July-Sept	2016	1122	98.7%	96.4%	~	97.1%	97.1%	~
Oct-Dec	2016	1014	98.8%	96.1%	~	98.2%	96.8%	~
Jan-Mar	2017	922	98.6%	95.9%	~	96.5%	96.4%	~
Apr-June	2017	973	98.4%	95.7%	~	96.3%	96.3%	~
July-Sept	2017	1114	98.7%	96.8%	~	97.4%	97.5%	96.8%
Oct-Dec	2017	1048	98.1%	94.5%	~	96.0%	95.5%	95.9%
Jan-Mar	2018	977	98.6%	95.5%	~	96.6%	96.5%	96.0%
Apr-June	2018	996	97.9%	94.3%	~	95.6%	95.3%	94.8%
July-Sept	2018	1064	98.6%	94.8%	~	96.1%	96.3%	95.9%
Oct-Dec	2018	991	97.4%	93.3%	~	93.8%	93.5%	93.8%
Jan-Mar	2019	962	97.5%	92.3%	~	96.9%	93.0%	92.4%
Apr-June	2019	959	97.0%	91.4%	~	92.5%	92.3%	92.5%
July-Sept	2019	1021	96.4%	92.8%	~	93.4%	92.8%	93.1%
Oct-Dec	2019	1035	96.6%	92.0%	~	95.6%	92.9%	92.6%
Jan-Mar	2020	940	95.6%	93.3%	~	93.4%	93.4%	93.3%
Apr-June	2020	975	96.7%	94.2%	~	94.1%	93.8%	94.4%
July-Sept	2020	987	97.7%	94.2%	~	95.1%	94.9%	94.8%
Oct-Dec	2020	925	96.4%	93.4%	~	94.5%	94.4%	94.1%
Jan-Mar	2021	936	97.2%	92.8%	~	93.5%	93.3%	93.2%
Apr-June	2021	885	96.8%	95.1%	~	95.6%	95.6%	95.1%
July-Sept	2021	965	95.8%	94.8%	~	95.9%	95.4%	94.8%
Oct-Dec	2021	919	95.9%	95.0%	~	95.5%	95.2%	95.1%
Jan-Mar	2022	925	95.9%	95.0%	~	94.7%	94.9%	94.9%
Apr-June	2022	886	97.0%	94.6%	~	94.8%	95.0%	94.1%
July-Sept	2022	924	95.8%	93.4%	~	94.3%	93.8%	93.7%
Oct-Dec	2022	973	95.7%	93.1%	~	96.3%	93.5%	93.3%
Jan-Mar	2023	929	95.4%	92.5%	~	93.2%	93.2%	92.5%
Apr-June	2023	889	96.0%	91.7%	~	92.9%	93.3%	92.6%
Jul-Sept	2023	1030	94.8%	92.0%	~	92.9%	92.6%	92.1%
Oct-Dec	2023	925	95.8%	92.3%	~	93.2%	92.6%	92.3%
Jan-Mar	2023	845	95.0%	90.4%	~	91.0%	90.8%	90.2%
Apr-June	2024	840	93.6%	90.7%	~	91.4%	91.4%	91.3%
Jul-Sept	2024	873	95.8%	92.7%	~	96.9%	93.6%	92.9%
ош-обрі	2027	010	55.070	UZ.1 /U	-	55.570	55.070	J2.370

^{*} children were 24 months old during this quarter

**DTap/IPV/Hib/HepB

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Haemophilus Influenzae type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017 Tet3 = Pert3 = Pol (IPV)3 =

HepB3 =

Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)Reporting commenced Jan-Mar 2020

Infant MenC = ~ Meningococcal serogroup C conjugate vaccine (2 doses under 12 months) reporting ceased in April 2013

PCV Booster = Pneumococcal conjugate booster vaccine (1 dose over 12 months) (introduced Sept 2006) Measles, mumps, and rubella vaccine (1 dose)

MMR1 =

Hib/MenC booster vaccine (1 dose) (introduced September 2006) Hib/MenC = Meningococcal serogroup B vaccine (3 doses) (introduced Sept 2015) MenB3 =